JP2019533660A5 - - Google Patents

Info

Publication number

JP2019533660A5

JP2019533660A5 JP2019518278A JP2019518278A JP2019533660A5 JP 2019533660 A5 JP2019533660 A5 JP 2019533660A5 JP 2019518278 A JP2019518278 A JP 2019518278A JP 2019518278 A JP2019518278 A JP 2019518278A JP 2019533660 A5 JP2019533660 A5 JP 2019533660A5

Authority

JP

Japan

Prior art keywords

renal failure

pharmaceutical composition

acute renal

composition according

patient

Prior art date

2017-10-05

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 208000009304 Acute Kidney Injury Diseases 0.000 claims description 42
• 208000033626 Renal failure acute Diseases 0.000 claims description 39
• 201000011040 acute kidney failure Diseases 0.000 claims description 39
• 150000001875 compounds Chemical class 0.000 claims description 20
• 150000003839 salts Chemical class 0.000 claims description 14
• 239000000126 substance Substances 0.000 claims description 13
• 239000003795 chemical substances by application Substances 0.000 claims description 6
• 239000003814 drug Substances 0.000 claims description 6
• 208000017169 kidney disease Diseases 0.000 claims description 6
• 238000001990 intravenous administration Methods 0.000 claims description 5
• 230000003589 nefrotoxic effect Effects 0.000 claims description 5
• 231100000381 nephrotoxic Toxicity 0.000 claims description 5
• 230000001154 acute effect Effects 0.000 claims description 4
• 229940079593 drug Drugs 0.000 claims description 4
• VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 4
• 230000001066 destructive effect Effects 0.000 claims description 3
• 238000004519 manufacturing process Methods 0.000 claims description 3
• 229930183010 Amphotericin Natural products 0.000 claims description 2
• QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 claims description 2
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
• 108010036949 Cyclosporine Proteins 0.000 claims description 2
• ZMJOVJSTYLQINE-UHFFFAOYSA-N Dichloroacetylene Chemical group ClC#CCl ZMJOVJSTYLQINE-UHFFFAOYSA-N 0.000 claims description 2
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
• 229930182566 Gentamicin Natural products 0.000 claims description 2
• 208000001953 Hypotension Diseases 0.000 claims description 2
• 206010021143 Hypoxia Diseases 0.000 claims description 2
• 206010028629 Myoglobinuria Diseases 0.000 claims description 2
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 2
• 208000001647 Renal Insufficiency Diseases 0.000 claims description 2
• 206010040047 Sepsis Diseases 0.000 claims description 2
• 231100000644 Toxic injury Toxicity 0.000 claims description 2
• XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 claims description 2
• 206010048302 Tubulointerstitial nephritis Diseases 0.000 claims description 2
• 229940009444 amphotericin Drugs 0.000 claims description 2
• APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 2
• CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 claims description 2
• 229960003866 cefaloridine Drugs 0.000 claims description 2
• 229960001265 ciclosporin Drugs 0.000 claims description 2
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
• 229960004316 cisplatin Drugs 0.000 claims description 2
• 229930182912 cyclosporin Natural products 0.000 claims description 2
• 206010012601 diabetes mellitus Diseases 0.000 claims description 2
• 201000010099 disease Diseases 0.000 claims description 2
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
• 229960002518 gentamicin Drugs 0.000 claims description 2
• 230000001434 glomerular Effects 0.000 claims description 2
• 208000006750 hematuria Diseases 0.000 claims description 2
• 230000036543 hypotension Effects 0.000 claims description 2
• 230000007954 hypoxia Effects 0.000 claims description 2
• 201000006370 kidney failure Diseases 0.000 claims description 2
• 208000019423 liver disease Diseases 0.000 claims description 2
• 208000012998 acute renal failure Diseases 0.000 claims 21
• 239000008194 pharmaceutical composition Substances 0.000 claims 19
• 208000037157 Azotemia Diseases 0.000 claims 1
• 206010065673 Nephritic syndrome Diseases 0.000 claims 1
• 208000028867 ischemia Diseases 0.000 claims 1
• 208000013223 septicemia Diseases 0.000 claims 1
• 238000001356 surgical procedure Methods 0.000 claims 1
• 230000003156 vasculitic effect Effects 0.000 claims 1
• 238000000034 method Methods 0.000 description 21
• LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
• 206010047115 Vasculitis Diseases 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 201000008383 nephritis Diseases 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 229940127557 pharmaceutical product Drugs 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1